Qiao Yanyan, Cao Jinyan, Xie Liangqun, Shi Xiaolin
Department of Reproductive Medicine, Basic Medical College, Capital Medical University, Beijing 100069, China.
Arch Pharm Res. 2009 Sep;32(9):1309-15. doi: 10.1007/s12272-009-1917-3. Epub 2009 Sep 26.
EGCG [(-)-epigallocatechin-3-gallate] has shown its antitumor ability and perhaps a potential regimen for cancer patients. The goal of this study was to investigate the effect of EGCG on human papilloma virus (HPV) positive cervical cancer cell lines. EGCG inhibited the growth of CaSki (HPV16 positive) and HeLa (HPV18 positive) cells in a time- and concentration-dependent manner. Cell cycle arrest and apoptosis were observed in two cell lines after EGCG exposure. More importantly, we focused on EGCG regulation ability on pivotal genes involved in cervical cancer: viral oncogenes E6/E7, estrogen receptor (ER) and aromatase. Our results suggested that EGCG may be suitable for prevention and treatment of cervical cancer.
表没食子儿茶素没食子酸酯[(-)-表没食子儿茶素-3-没食子酸酯]已显示出其抗肿瘤能力，可能是癌症患者的一种潜在治疗方案。本研究的目的是探讨表没食子儿茶素没食子酸酯对人乳头瘤病毒(HPV)阳性宫颈癌细胞系的影响。表没食子儿茶素没食子酸酯以时间和浓度依赖性方式抑制CaSki(HPV16阳性)和HeLa(HPV18阳性)细胞的生长。表没食子儿茶素没食子酸酯处理后，在两种细胞系中观察到细胞周期停滞和凋亡。更重要的是，我们关注表没食子儿茶素没食子酸酯对宫颈癌相关关键基因的调控能力：病毒癌基因E6/E7、雌激素受体(ER)和芳香化酶。我们的结果表明，表没食子儿茶素没食子酸酯可能适用于宫颈癌的预防和治疗。
